Daiichi Sankyo, “Olmesartan’s removal of insurance benefit is not revocation of approval”
“The de
cision is only removal from the insurance benefit, not revocation of approval. We will continue adjusting domestic actions with the Ministry of Food and Drug Safety.”
When it came to the olmesartan’s French expulsion crisis, Daiichi Sankyo finally left a comment.
On the 11th, the Ministr...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
